Literature DB >> 17411378

Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes.

Geraldine M A Gillespie1, Arman Bashirova, Tao Dong, Daniel W McVicar, Sarah L Rowland-Jones, Mary Carrington.   

Abstract

In HIV-1 infection, the synergistic association of a subset of Bw4 MHC class I molecules and the activating killer inhibitory receptor (KIR), KIR3DS1, with prolonged AIDS-free survival has been reported. As KIRs represent a diverse group of MHC class I receptors, we questioned whether Bw4 MHC class I molecules expressing isoleucine at position 80 (Bw4Ile80) and in complex with HIV-1-derived T cell epitopes represented KIR3DS1 ligands. MHC class I tetramers are powerful tools for the detection of T cell receptor-MHC class I interactions, and have recently been used to evaluate KIR-MHC class I binding ex vivo. Specifically, this approach has been successfully utilized to assess binding of Bw4 MHC class I tetramers to KIR3DL1, an inhibitory KIR and allele of KIR3DS1. In this study we generated a diverse panel of HIV-1-specific Bw4Ile80 MHC class I tetramers and tested its ability to bind transiently expressed KIR3DS1 on 293-T cells. Using flow cytometry analysis, the expression of KIR3DS1 on 293-T cells was confirmed by anti-FLAG BioM2 staining, prior to incubation with PE-conjugated MHC class I tetramers. Despite choosing a broad array of peptide epitopes and diverse Bw4Ile80 MHC class I molecules, we were unable to detect tetramer binding to KIR3DS1. We speculate that our negative finding may be a consequence of the MHC class I molecules and peptide epitopes chosen, but could also relate to key amino acid differences that distinguish KIR3DS1 from KIR3DL1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17411378     DOI: 10.1089/aid.2006.0165

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  41 in total

1.  Inference on the strength of balancing selection for epistatically interacting loci.

Authors:  Erkan Ozge Buzbas; Paul Joyce; Noah A Rosenberg
Journal:  Theor Popul Biol       Date:  2011-01-26       Impact factor: 1.570

Review 2.  Evolutionary struggles between NK cells and viruses.

Authors:  Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

Review 3.  Role of natural killer cells in HIV pathogenesis.

Authors:  Jeffrey Ward; Edward Barker
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

Review 4.  DCs and NK cells: critical effectors in the immune response to HIV-1.

Authors:  Marcus Altfeld; Lena Fadda; Davor Frleta; Nina Bhardwaj
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

Review 5.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

6.  Association of KIR3DL1/S1 and HLA-Bw4 with CD4 T cell counts in HIV-infected Mexican mestizos.

Authors:  Daniel Hernández-Ramírez; Mario A Esparza-Pérez; José L Ramirez-Garcialuna; J Rafael Arguello; Peter B Mandeville; Daniel E Noyola; Christian A García-Sepúlveda
Journal:  Immunogenetics       Date:  2015-06-03       Impact factor: 2.846

Review 7.  KIRigami: the case for studying NK cell receptors in SIV+ macaques.

Authors:  Benjamin Bimber; David H O'Connor
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  Co-evolution of MHC class I and variable NK cell receptors in placental mammals.

Authors:  Lisbeth A Guethlein; Paul J Norman; Hugo G Hilton; Peter Parham
Journal:  Immunol Rev       Date:  2015-09       Impact factor: 12.988

Review 9.  Structural insights into activation of antiviral NK cell responses.

Authors:  Kathryn A Finton; Roland K Strong
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

10.  KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Authors:  Christopher J Forlenza; Jeanette E Boudreau; Junting Zheng; Jean-Benoît Le Luduec; Elizabeth Chamberlain; Glenn Heller; Nai-Kong V Cheung; Katharine C Hsu
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.